Covered recipient · General Payments record
BRAD P GLICK
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$367,021.69
349 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $295,363.50 | 98 |
| Consulting Fee | $34,735.50 | 13 |
| Travel and Lodging | $18,252.38 | 34 |
| Food and Beverage | $8,151.18 | 198 |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,000.00 | 3 |
| Honoraria | $3,500.00 | 1 |
| Education | $19.13 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $45,274.79 | 41 |
| Janssen Biotech, Inc. | $41,925.62 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $41,337.19 | 20 |
| E.R. Squibb & Sons, L.L.C. | $32,510.76 | 29 |
| Dermavant Sciences, Inc. | $31,918.55 | 25 |
| UCB, Inc. | $29,112.01 | 24 |
| Arcutis Biotherapeutics, Inc. | $26,832.40 | 30 |
| Lilly USA, LLC | $24,956.14 | 18 |
| Amgen Inc. | $16,672.17 | 11 |
| Incyte Corporation | $16,268.21 | 21 |
| Sun Pharmaceutical Industries Inc. | $14,807.19 | 14 |
| Regeneron Healthcare Solutions, Inc. | $10,206.80 | 12 |
| GENZYME CORPORATION | $9,710.34 | 8 |
| PFIZER INC. | $8,624.17 | 11 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $7,473.23 | 11 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,505.46 | 14 |
| Hikma Pharmaceuticals USA | $3,500.00 | 1 |
| Galderma Laboratories, L.P. | $1,981.87 | 8 |
| LEO Pharma Inc. | $155.27 | 5 |
| Janssen Research & Development, LLC | $105.29 | 1 |
| Biofrontera Inc. | $62.49 | 2 |
| Verrica Pharmaceuticals Inc. | $45.23 | 2 |
| Organogenesis Inc. | $19.71 | 1 |
| Smith+Nephew, Inc. | $16.80 | 1 |
Page 2 of 7; records 51–100 of 349 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRAD P GLICK
NPI 1235134818 · CMS profile ID 55271
Allopathic & Osteopathic Physicians / Dermatology
MARGATE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 7; records 51–100 of 349 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1235134818?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRAD P GLICK, NPI 1235134818, CMS profile ID 55271. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 349 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235134818?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). BRAD P GLICK, NPI 1235134818, CMS profile ID 55271. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 349 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235134818?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- BRAD P GLICK, NPI 1235134818, CMS profile ID 55271, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 349 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1235134818?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
349 matching records · $367,021.69 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 349.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $21.37 | 10/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031291679 | CMS |
| Dermavant Sciences, Inc. | $3,200.00 | 10/26/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991190749 | CMS |
| Arcutis Biotherapeutics, Inc. | $19.75 | 10/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044660801 | CMS |
| Janssen Biotech, Inc. | $25.00 | 10/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091485 | CMS |
| Sun Pharmaceutical Industries Inc. | $21.50 | 10/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053802885 | CMS |
| Janssen Biotech, Inc. | $1,650.00 | 10/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091435 | CMS |
| Janssen Biotech, Inc. | $3,713.00 | 10/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091445 | CMS |
| Amgen Inc. | $29.17 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020544947 | CMS |
| Dermavant Sciences, Inc. | $121.50 | 10/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991190745 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,756.00 | 10/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015055961 | CMS |
| ABBVIE INC. | $3,375.00 | 10/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997350571 | CMS |
| Novartis Pharmaceuticals Corporation | $75.74 | 10/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992197135 | CMS |
| UCB, Inc. | $28.21 | 10/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021650523 | CMS |
| ABBVIE INC. | $124.90 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997350567 | CMS |
| ABBVIE INC. | $856.00 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997350569 | CMS |
| Regeneron Healthcare Solutions, Inc. | $32.82 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999188265 | CMS |
| ABBVIE INC. | $9.69 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997350565 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,940.00 | 10/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996465505 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,940.00 | 10/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997116301 | CMS |
| Verrica Pharmaceuticals Inc. | $25.55 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 989120957 | CMS |
| Janssen Biotech, Inc. | $23.81 | 10/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091493 | CMS |
| Janssen Biotech, Inc. | $116.06 | 10/07/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091429 | CMS |
| Arcutis Biotherapeutics, Inc. | $3,375.00 | 10/05/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044660643 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.00 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996465485 | CMS |
| Galderma Laboratories, L.P. | $3.86 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059697291 | CMS |
| Smith+Nephew, Inc. | $16.80 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 1053355707 | CMS |
| Incyte Corporation | $19.99 | 10/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044673317 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $20.73 | 10/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051600829 | CMS |
| Arcutis Biotherapeutics, Inc. | $12.46 | 10/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044660825 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $280.00 | 10/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051600803 | CMS |
| Sun Pharmaceutical Industries Inc. | $4,565.00 | 10/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053802877 | CMS |
| Sun Pharmaceutical Industries Inc. | $799.50 | 10/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053802879 | CMS |
| Sun Pharmaceutical Industries Inc. | $121.87 | 10/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053802883 | CMS |
| Arcutis Biotherapeutics, Inc. | $2,250.00 | 10/02/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044660631 | CMS |
| Arcutis Biotherapeutics, Inc. | $15.34 | 10/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044660813 | CMS |
| Novartis Pharmaceuticals Corporation | $27.41 | 09/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992197125 | CMS |
| Arcutis Biotherapeutics, Inc. | $648.00 | 09/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044660899 | CMS |
| Dermavant Sciences, Inc. | $3,200.00 | 09/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991190741 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.25 | 09/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015055945 | CMS |
| E.R. Squibb & Sons, L.L.C. | $582.84 | 09/25/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015055953 | CMS |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 09/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015055971 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $2,100.00 | 09/22/2023 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051600787 | CMS |
| PFIZER INC. | $13.74 | 09/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050687637 | CMS |
| GENZYME CORPORATION | $37.35 | 09/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049763284 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $3,500.00 | 09/18/2023 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051600793 | CMS |
| Sun Pharmaceutical Industries Inc. | $5.53 | 09/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053802855 | CMS |
| Janssen Biotech, Inc. | $3,713.00 | 09/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091407 | CMS |
| Lilly USA, LLC | $1,600.00 | 09/14/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031292127 | CMS |
| ABBVIE INC. | $29.16 | 09/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997350563 | CMS |
| Janssen Biotech, Inc. | $122.08 | 09/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988091419 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $344,231.01 | 142 |
| PY2024 | Principal investigator | $874,375.49 | 397 |
| PY2023 | Principal investigator | $152,321.61 | 58 |
| PY2022 | Principal investigator | $96,349.78 | 31 |
| PY2021 | Principal investigator | $208,888.57 | 30 |
| PY2020 | Recipient | $324.60 | 1 |
| PY2020 | Principal investigator | $225,111.96 | 38 |
| PY2019 | Principal investigator | $119,709.96 | 18 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
142 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202533001 |
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202533003 |
| Principal investigator 1 | Amgen Inc. | $3,600.00 | 12/24/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | No dispute reported | 06/30/2026 | 1246641996 |
| Principal investigator 1 | Amgen Inc. | $7,100.00 | 12/24/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246642000 |
| Principal investigator 1 | ABBVIE INC. | $1,892.10 | 12/04/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527062 |
| Principal investigator 1 | ABBVIE INC. | $3,104.13 | 12/04/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202527064 |
| Principal investigator 1 | ABBVIE INC. | $21,865.65 | 12/04/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527066 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537415 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537420 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537424 |
| Principal investigator 1 | Incyte Corporation | $1,800.00 | 11/12/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537441 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 11/12/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537444 |
| Principal investigator 1 | ABBVIE INC. | $35,066.25 | 11/05/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522849 |
| Principal investigator 1 | ABBVIE INC. | $2,167.50 | 11/04/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202521065 |
| Principal investigator 1 | ABBVIE INC. | $7,001.64 | 11/04/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202521067 |
| Principal investigator 1 | ABBVIE INC. | $2,002.00 | 11/04/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202521069 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,000.00 | 10/29/2025 | Non-covered Recipient Entity Gsi Clinical Research | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226083305 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 10/15/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537402 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 10/15/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537428 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 10/15/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537432 |
| Principal investigator 1 | Incyte Corporation | $1,800.00 | 10/13/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537406 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 10/13/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537437 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 10/13/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537449 |
| Principal investigator 1 | ABBVIE INC. | $34,800.30 | 10/09/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202514205 |
| Principal investigator 1 | Incyte Corporation | $1,413.00 | 09/10/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537393 |
| Principal investigator 1 | ABBVIE INC. | $2,502.50 | 09/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507779 |
| Principal investigator 1 | ABBVIE INC. | $3,004.68 | 09/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202507781 |
| Principal investigator 1 | ABBVIE INC. | $500.50 | 08/06/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202503089 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 08/05/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202501772 |
| Principal investigator 1 | Incyte Corporation | $1,984.50 | 07/09/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537397 |
| Principal investigator 1 | ABBVIE INC. | $2,380.00 | 07/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202495491 |
| Principal investigator 1 | ABBVIE INC. | $1,695.00 | 07/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202495493 |
| Principal investigator 1 | ABBVIE INC. | $1,636.20 | 07/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495495 |
| Principal investigator 1 | ABBVIE INC. | $500.50 | 07/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202495497 |
| Principal investigator 1 | ABBVIE INC. | $3,854.22 | 07/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202495613 |
| Principal investigator 1 | ABBVIE INC. | $6,858.90 | 06/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202488757 |
| Principal investigator 1 | ABBVIE INC. | $3,681.45 | 06/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202488759 |
| Principal investigator 1 | ABBVIE INC. | $2,054.00 | 06/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202489477 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,628.00 | 05/28/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193776 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,628.00 | 05/28/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 05/21/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184197479 |
| Principal investigator 1 | ABBVIE INC. | $4,483.69 | 05/07/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482815 |
| Principal investigator 1 | ABBVIE INC. | $2,054.00 | 05/07/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202482885 |
| Principal investigator 1 | ABBVIE INC. | $3,388.50 | 05/07/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202482887 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $454.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193809 |
| Principal investigator 1 | Janssen Research & Development, LLC | $508.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193816 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193832 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193850 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,526.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193874 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193909 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $704.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193958 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193964 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,526.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194010 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,526.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194044 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194051 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,526.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194057 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,895.00 | 05/07/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194065 |
| Principal investigator 1 | ABBVIE INC. | $5,500.00 | 05/06/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202481533 |
| Principal investigator 1 | Incyte Corporation | $1,172.70 | 05/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,628.00 | 04/28/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,628.00 | 04/28/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194016 |
| Principal investigator 1 | Incyte Corporation | $2,205.00 | 04/09/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537325 |
| Principal investigator 1 | ABBVIE INC. | $2,054.00 | 04/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202469233 |
| Principal investigator 1 | ABBVIE INC. | $1,338.60 | 04/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202471574 |
| Principal investigator 1 | ABBVIE INC. | $2,291.10 | 04/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202471577 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537312 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537321 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537329 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537333 |
| Principal investigator 1 | Incyte Corporation | $12.36 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537337 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537342 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537346 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537349 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537353 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537358 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537362 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537366 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537370 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537373 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537377 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537381 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537385 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,628.00 | 03/24/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 03/24/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193935 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 03/24/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193983 |
| Principal investigator 1 | Incyte Corporation | $1,393.20 | 03/12/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537182 |
| Principal investigator 1 | ABBVIE INC. | $6,345.00 | 03/07/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202460467 |
| Principal investigator 1 | ABBVIE INC. | $6,587.46 | 03/07/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202460471 |
| Principal investigator 1 | ABBVIE INC. | $1,001.00 | 03/07/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202460637 |
| Principal investigator 1 | Incyte Corporation | $125.95 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537228 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537232 |
| Principal investigator 1 | Incyte Corporation | $236.52 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537245 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537250 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537255 |
| Principal investigator 1 | Incyte Corporation | $406.20 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537259 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537271 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537275 |
| Principal investigator 1 | Incyte Corporation | $19.44 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537281 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537297 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 03/03/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193794 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,678.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193824 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,916.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193942 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,678.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,678.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 02/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175194000 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,425.00 | 02/21/2025 | Non-covered Recipient Entity Glick Skin Institute | A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235997087 |
| Principal investigator 1 | Incyte Corporation | $1,645.00 | 02/10/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537236 |
| Principal investigator 1 | Incyte Corporation | $1,548.00 | 02/10/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537263 |
| Principal investigator 1 | Incyte Corporation | $1,548.00 | 02/10/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537267 |
| Principal investigator 1 | ABBVIE INC. | $4,320.00 | 02/06/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202447309 |
| Principal investigator 1 | ABBVIE INC. | $11,635.09 | 02/06/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202448295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,678.00 | 01/27/2025 | Non-covered Recipient Entity Gsi Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175193860 |
| Principal investigator 1 | Incyte Corporation | $1,710.00 | 01/15/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537220 |
| Principal investigator 1 | Incyte Corporation | $1,658.70 | 01/15/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537224 |
| Principal investigator 1 | Incyte Corporation | $1,073.90 | 01/15/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537285 |
| Principal investigator 1 | Eli Lilly and Company | $4,000.00 | 01/10/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187881016 |
| Principal investigator 1 | ABBVIE INC. | $4,486.40 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202433839 |
| Principal investigator 1 | ABBVIE INC. | $4,504.50 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202434800 |
| Principal investigator 1 | ABBVIE INC. | $2,077.05 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH LLC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202434804 |
| Principal investigator 1 | Incyte Corporation | $190.80 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537185 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537188 |
| Principal investigator 1 | Incyte Corporation | $206.70 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537193 |
| Principal investigator 1 | Incyte Corporation | $132.50 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537197 |
| Principal investigator 1 | Incyte Corporation | $100.70 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537201 |
| Principal investigator 1 | Incyte Corporation | $127.20 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537205 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537209 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537216 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537240 |
| Principal investigator 1 | Incyte Corporation | $185.50 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537289 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537293 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity GSI CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240537308 |